// App-Quantinova.ai

8007 : Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.

Researchers

Presenter

  • Cara Ann Rosenbaum

Principal Investigators

  • Leonor Ano Stephens

  • Vishal Kukreti

  • Jeffrey A. Zonder

  • Craig Cole

  • Todd M. Zimmerman

  • Donna Ellen Reece

  • Jesus G. Berdeja

  • Erica Severson

  • Andrea Revethis

  • Brittany Wolfe

  • Kathryn McDonnell

  • Jennifer Nam

  • Kent A. Griffith

  • Andrzej J. Jakubowiak

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Karmanos Cancer Institute, Detroit, MI

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Sarah Cannon Research Institute, Nashville, TN

  • The University of Chicago Medical Center, Chicago, IL

  • University of Michigan, Ann Arbor, MI

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • carfilzomib Intravenous

Outcome

  • N/A

Study Design

  • Multicenteric

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT01665794

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved